The Edge of Exclusivity: From Revenue Cliff to Biosimilar Slope
News
05/05/2026
As we move through 2026 towards 2030, the pharmaceutical industry is no longer approaching the ‘super cliff’ but has already stepped off the edge and is part way down it.
Read more